Digital therapeutics for chronic care
Digital therapeutics
Treating cardiometabolic diseases with prescription software
A global silent epidemic
Problem
Cardiometabolic diseases, including heart disease and type 2 diabetes are placing a massive burden on healthcare systems worldwide.
More than 1,5 billion people globally are living with metabolic syndrome - a chronic condition that greatly increases the risk of heart disease and type 2 diabetes. It is a cluster of risk factors, including elevated blood pressure, cholesterol imbalance, impaired glucose tolerance and obesity. The prevalence is increasing rapidly.
Due to shortage of physicians and lack of evidence-based digital tools, there is a growing care gap for personalised cardiometabolic care. This leaves patients with very little support in-between doctor visits leading to progression of the disease and hundreds of billions in preventable medical cost each year.
Digital therapeutics
Solution
AI-powered prescription digital therapeutics for treating cardiometabolic diseases.
Cardiometabolic risk calculator
Evidence-based intervention programs
Connected wearables and medical devices
Plug & play remote patient monitoring
Biometric health monitoring
Digital screening tool for practices
A new class of medicine
Research & development
Digital therapeutics (DTx) are clinically validated software applications prescribed by physicians to monitor and treat a specific disease.
Our digital therapeutics are developed according to strict regulatory guidelines and validated with clinical trials. They offer a novel way of treating the growing number of patients with chronic diseases while keeping associated costs down.
We are currently running a €1 million R&D project that brings together world-class scientists, engineers and medical experts to develop this unique evidence-based Software as a Medical Device (SaMD) platform.
This project is funded by European Regional Development Fund and Enterprise Estonia in the sum of 772 500,00 euros.